Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non‐small cell lung cancer: Updated follow‐up results from two phase II trials

BACKGROUND: There are two main choices of administration route of recombinant human endostatin (Endostar) available and the treatment options of concurrent chemoradiotherapy (CCRT) have changed over time. The aim of this study was to observe the long‐term efficacy and safety of different administrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Honglian, Ma, Zhouguang, Hui, Fang, PENG, Lujun, Zhao, Dongming, Li, Yujin, Xu, Yong, Bao, Liming, Xu, Yirui, Zhai, Xiao, Hu, Jin, Wang, Yue, Kong, Lvhua, Wang, Ming, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113061/
https://www.ncbi.nlm.nih.gov/pubmed/32068962
http://dx.doi.org/10.1111/1759-7714.13333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113061/
https://www.ncbi.nlm.nih.gov/pubmed/32068962
http://dx.doi.org/10.1111/1759-7714.13333

Ejemplares similares